Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioterrorism Product Research Tax Credit Expanded Under Lieberman Bill

Executive Summary

Bioterrorism product research tax credits would be expanded to include companies with tax liability, such as larger biotech and pharma firms, under reworked legislation being developed by Sen. Joseph Lieberman (D-Conn.)

You may also be interested in...



Orphan Vaccine Centers Could Produce Bioterror Products, NRC Report Says

Government-owned, contractor-operated facilities for orphan vaccines could facilitate mass manufacture of counterterrorism agents, the National Research Council suggested in a June 25 report

Orphan Vaccine Centers Could Produce Bioterror Products, NRC Report Says

Government-owned, contractor-operated facilities for orphan vaccines could facilitate mass manufacture of counterterrorism agents, the National Research Council suggested in a June 25 report

Patent Incentive For Bioterrorism Research Offered In Lieberman Bill

Pharmaceuticals approved for use as anti-bioterrorism agents would be eligible for full patent term restoration under legislation introduced by Sen. Joe Lieberman (D-Conn.) on Dec. 4

Related Content

UsernamePublicRestriction

Register

PS040001

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel